Stamatis-Nick C Liossis1, Chrysanthi Staveri2. 1. Division of Rheumatology, Department of Internal Medicine, University of Patras Medical School and Patras University Hospital, 26500 Rion, Patras, Greece. snliossis@med.upatras.gr. 2. Division of Rheumatology, Department of Internal Medicine, University of Patras Medical School and Patras University Hospital, 26500 Rion, Patras, Greece.
Abstract
PURPOSE OF REVIEW: B cells have been targeted recently by novel therapeutic approaches in patients with SLE. In this review, we discuss recent data that have emerged on this issue placing special emphasis in studies published during the last 5 years. RECENT FINDINGS: Despite the negative results stemming from double-blind placebo-controlled studies, B cell depletion with rituximab is indeed employed worldwide, particularly in standard treatment refractory lupus, with promising results. In addition, positive experience with the approved agent belimumab is steadily increasing. Both regimens have an acceptable safety profile. Identification of B cells as a therapeutic target in SLE has been so far rewarding, since one such treatment, belimumab, has been the only regulatory authority-approved medication in SLE for over half a century. Focusing specifically on autoreactive instead of non-specifically altering/depleting lupus, B cells may lead to more rational treatment modes.
PURPOSE OF REVIEW: B cells have been targeted recently by novel therapeutic approaches in patients with SLE. In this review, we discuss recent data that have emerged on this issue placing special emphasis in studies published during the last 5 years. RECENT FINDINGS: Despite the negative results stemming from double-blind placebo-controlled studies, B cell depletion with rituximab is indeed employed worldwide, particularly in standard treatment refractory lupus, with promising results. In addition, positive experience with the approved agent belimumab is steadily increasing. Both regimens have an acceptable safety profile. Identification of B cells as a therapeutic target in SLE has been so far rewarding, since one such treatment, belimumab, has been the only regulatory authority-approved medication in SLE for over half a century. Focusing specifically on autoreactive instead of non-specifically altering/depleting lupus, B cells may lead to more rational treatment modes.
Entities:
Keywords:
B cells; BLyS; Belimumab; Rituximab; Systemic lupus erythematosus
Authors: Eduardo F Mysler; Alberto J Spindler; Renato Guzman; Marc Bijl; David Jayne; Richard A Furie; Frédéric A Houssiau; Jorn Drappa; David Close; Romeo Maciuca; Kajal Rao; Saba Shahdad; Paul Brunetta Journal: Arthritis Rheum Date: 2013-09
Authors: D A Isenberg; M Petri; K Kalunian; Y Tanaka; M B Urowitz; R W Hoffman; M Morgan-Cox; N Iikuni; M Silk; D J Wallace Journal: Ann Rheum Dis Date: 2015-09-03 Impact factor: 19.103
Authors: Joyce S Hui-Yuen; Arthi Reddy; Jennifer Taylor; Xiaoqing Li; Andrew H Eichenfield; Liza M Bermudez; Amy J Starr; Lisa F Imundo; Jill Buyon; Richard A Furie; Diane L Kamen; Susan Manzi; Michelle Petri; Rosalind Ramsey-Goldman; Ronald F van Vollenhoven; Daniel J Wallace; Anca Askanase Journal: J Rheumatol Date: 2015-11-01 Impact factor: 4.666
Authors: Ellen M Ginzler; Daniel J Wallace; Joan T Merrill; Richard A Furie; William Stohl; W Winn Chatham; Arthur Weinstein; James D McKay; W Joseph McCune; Z John Zhong; William W Freimuth; Michelle A Petri Journal: J Rheumatol Date: 2013-11-01 Impact factor: 4.666
Authors: William Stohl; Joan T Merrill; R John Looney; Jill Buyon; Daniel J Wallace; Michael H Weisman; Ellen M Ginzler; Blaire Cooke; Donna Holloway; Arunan Kaliyaperumal; Kameswara Rao Kuchimanchi; Tsui Chern Cheah; Erik Rasmussen; John Ferbas; Shelley S Belouski; Wayne Tsuji; Debra J Zack Journal: Arthritis Res Ther Date: 2015-08-20 Impact factor: 5.156
Authors: I N Bruce; M Urowitz; R van Vollenhoven; C Aranow; J Fettiplace; M Oldham; B Wilson; C Molta; D Roth; D Gordon Journal: Lupus Date: 2016-03-01 Impact factor: 2.911
Authors: Megan E B Clowse; Daniel J Wallace; Richard A Furie; Michelle A Petri; Marilyn C Pike; Piotr Leszczyński; C Michael Neuwelt; Kathryn Hobbs; Mauro Keiserman; Liliana Duca; Kenneth C Kalunian; Catrinel Galateanu; Sabine Bongardt; Christian Stach; Carolyn Beaudot; Brian Kilgallen; Caroline Gordon Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: Erin A Yamamoto; Jane K Nguyen; Jessica Liu; Emma Keller; Nicole Campbell; Cun-Jin Zhang; Howard R Smith; Xiaoxia Li; Trine N Jørgensen Journal: Nutrients Date: 2020-01-22 Impact factor: 5.717